Surinder Kaur Khelae, Kyoung Ryul Julian Chun, Christian Drephal, Fernando Scazzuso, Fred J Kueffer, Kelly A van Bragt, Thorsten Lawrenz, Derick Todd, Paweł Ptaszyński, Csaba Földesi
{"title":"冷冻球囊消融后医疗保健利用的真实世界性别差异：来自冷冻全球登记的2年结果","authors":"Surinder Kaur Khelae, Kyoung Ryul Julian Chun, Christian Drephal, Fernando Scazzuso, Fred J Kueffer, Kelly A van Bragt, Thorsten Lawrenz, Derick Todd, Paweł Ptaszyński, Csaba Földesi","doi":"10.3389/fcvm.2025.1549002","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cryoballoon ablation (CBA) is a well-established treatment for atrial fibrillation (AF). However, evidence on the impact of sex on outcome is sparse. This real-world analysis aims to describe outcome after CBA in both sexes.</p><p><strong>Methods: </strong>This registry is an ongoing, global evaluation of CBA procedures in standard-of-care practice. Females undergoing CBA were compared to males at baseline and 12-, and 24-months post-ablation. Serious procedure-related adverse event rate, rate of atrial arrhythmia (AA) recurrence, repeat ablation, hospitalization, cardioversion, and quality-of-life (QoL; EQ-5D-3l) were compared.</p><p><strong>Results: </strong>Of 3,089 patients with 12-month follow-up, 1,136 (36.8%) were female; and a subset of 1,099 patients (400 female) were followed through 24 months. Females presented with different comorbidities at baseline. The complication rate was low overall in females (3.9%) and males (2.7%, <i>p</i> = 0.07). At 24-month follow-up, the rate of AA recurrence was 25.0% in females and 22.1% in males and female sex was a predictor of AA recurrence (HR adj = 1.21, <i>p</i> = 0.047) and rehospitalizations (HR adj = 1.25, <i>p</i> = 0.03) in a propensity score adjusted analysis. In addition, females stayed in the hospital longer compared to males during the index ablation procedure (47.9% with 2 or more days in hospital vs. 39.3% in males, <i>p</i> < 0.01), as well as during the first hospital stay post-ablation (78.2% with 2 or more days in hospital vs. 60.2% in males, <i>p</i> < 0.01). QoL improved from baseline to 12 months in females (0.85 ± 0.15-0.90 ± 0.13) and males (0.91 ± 0.13-0.94 ± 0.11) and remained high at 24 months.</p><p><strong>Discussion: </strong>CBA performed according to standard-of-care practice was safe in both sexes. The efficacy of CBA is marginally lower in females, but 75% of females remained free from AA recurrence at 24-months and reported a meaningful improvement in QoL post ablation.</p><p><strong>Systematic review registration: </strong>https://clinicaltrials.gov/ct2/show/NCT02752737, The Cryo Global Registry (NCT02752737).</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1549002"},"PeriodicalIF":2.8000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170535/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-world sex differences in healthcare utilization after cryoballoon ablation: 2-year outcomes from the Cryo Global Registry.\",\"authors\":\"Surinder Kaur Khelae, Kyoung Ryul Julian Chun, Christian Drephal, Fernando Scazzuso, Fred J Kueffer, Kelly A van Bragt, Thorsten Lawrenz, Derick Todd, Paweł Ptaszyński, Csaba Földesi\",\"doi\":\"10.3389/fcvm.2025.1549002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Cryoballoon ablation (CBA) is a well-established treatment for atrial fibrillation (AF). However, evidence on the impact of sex on outcome is sparse. This real-world analysis aims to describe outcome after CBA in both sexes.</p><p><strong>Methods: </strong>This registry is an ongoing, global evaluation of CBA procedures in standard-of-care practice. Females undergoing CBA were compared to males at baseline and 12-, and 24-months post-ablation. Serious procedure-related adverse event rate, rate of atrial arrhythmia (AA) recurrence, repeat ablation, hospitalization, cardioversion, and quality-of-life (QoL; EQ-5D-3l) were compared.</p><p><strong>Results: </strong>Of 3,089 patients with 12-month follow-up, 1,136 (36.8%) were female; and a subset of 1,099 patients (400 female) were followed through 24 months. Females presented with different comorbidities at baseline. The complication rate was low overall in females (3.9%) and males (2.7%, <i>p</i> = 0.07). At 24-month follow-up, the rate of AA recurrence was 25.0% in females and 22.1% in males and female sex was a predictor of AA recurrence (HR adj = 1.21, <i>p</i> = 0.047) and rehospitalizations (HR adj = 1.25, <i>p</i> = 0.03) in a propensity score adjusted analysis. In addition, females stayed in the hospital longer compared to males during the index ablation procedure (47.9% with 2 or more days in hospital vs. 39.3% in males, <i>p</i> < 0.01), as well as during the first hospital stay post-ablation (78.2% with 2 or more days in hospital vs. 60.2% in males, <i>p</i> < 0.01). QoL improved from baseline to 12 months in females (0.85 ± 0.15-0.90 ± 0.13) and males (0.91 ± 0.13-0.94 ± 0.11) and remained high at 24 months.</p><p><strong>Discussion: </strong>CBA performed according to standard-of-care practice was safe in both sexes. The efficacy of CBA is marginally lower in females, but 75% of females remained free from AA recurrence at 24-months and reported a meaningful improvement in QoL post ablation.</p><p><strong>Systematic review registration: </strong>https://clinicaltrials.gov/ct2/show/NCT02752737, The Cryo Global Registry (NCT02752737).</p>\",\"PeriodicalId\":12414,\"journal\":{\"name\":\"Frontiers in Cardiovascular Medicine\",\"volume\":\"12 \",\"pages\":\"1549002\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170535/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Cardiovascular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fcvm.2025.1549002\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1549002","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
低温球囊消融（CBA）是一种成熟的治疗心房颤动（AF）的方法。然而，关于性对结果影响的证据很少。这个现实世界的分析旨在描述男女参加CBA后的结果。方法：本注册表是对标准护理实践中CBA程序的持续、全面评估。在基线、消融后12个月和24个月对接受CBA的女性进行比较。严重手术相关不良事件发生率、房性心律失常（AA）复发率、重复消融率、住院率、心律转复率和生活质量（QoL）；EQ-5D-3l)进行比较。结果：随访12个月的3089例患者中，女性1136例（36.8%）；1099名患者（400名女性）被随访了24个月。女性在基线时表现出不同的合并症。并发症发生率总体上女性低（3.9%），男性低（2.7%,p = 0.07）。在24个月的随访中，女性AA复发率为25.0%，男性为22.1%，在倾向评分调整分析中，女性是AA复发率（HR adj = 1.21, p = 0.047）和再住院率（HR adj = 1.25, p = 0.03）的预测因子。此外，在指数消融过程中，女性住院时间比男性更长（47.9%住院时间为2天或更长，男性为39.3%）。CBA在女性中的疗效略低，但75%的女性在24个月时没有AA复发，并报告了消融后生活质量的显着改善。系统评价注册：https://clinicaltrials.gov/ct2/show/NCT02752737, The Cryo Global Registry （NCT02752737）。
Real-world sex differences in healthcare utilization after cryoballoon ablation: 2-year outcomes from the Cryo Global Registry.
Introduction: Cryoballoon ablation (CBA) is a well-established treatment for atrial fibrillation (AF). However, evidence on the impact of sex on outcome is sparse. This real-world analysis aims to describe outcome after CBA in both sexes.
Methods: This registry is an ongoing, global evaluation of CBA procedures in standard-of-care practice. Females undergoing CBA were compared to males at baseline and 12-, and 24-months post-ablation. Serious procedure-related adverse event rate, rate of atrial arrhythmia (AA) recurrence, repeat ablation, hospitalization, cardioversion, and quality-of-life (QoL; EQ-5D-3l) were compared.
Results: Of 3,089 patients with 12-month follow-up, 1,136 (36.8%) were female; and a subset of 1,099 patients (400 female) were followed through 24 months. Females presented with different comorbidities at baseline. The complication rate was low overall in females (3.9%) and males (2.7%, p = 0.07). At 24-month follow-up, the rate of AA recurrence was 25.0% in females and 22.1% in males and female sex was a predictor of AA recurrence (HR adj = 1.21, p = 0.047) and rehospitalizations (HR adj = 1.25, p = 0.03) in a propensity score adjusted analysis. In addition, females stayed in the hospital longer compared to males during the index ablation procedure (47.9% with 2 or more days in hospital vs. 39.3% in males, p < 0.01), as well as during the first hospital stay post-ablation (78.2% with 2 or more days in hospital vs. 60.2% in males, p < 0.01). QoL improved from baseline to 12 months in females (0.85 ± 0.15-0.90 ± 0.13) and males (0.91 ± 0.13-0.94 ± 0.11) and remained high at 24 months.
Discussion: CBA performed according to standard-of-care practice was safe in both sexes. The efficacy of CBA is marginally lower in females, but 75% of females remained free from AA recurrence at 24-months and reported a meaningful improvement in QoL post ablation.
Systematic review registration: https://clinicaltrials.gov/ct2/show/NCT02752737, The Cryo Global Registry (NCT02752737).
期刊介绍：
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
